Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) FCF Margin (2016 - 2025)

Ocular Therapeutix has reported FCF Margin over the past 13 years, most recently at 486.94% for Q4 2025.

  • Quarterly results put FCF Margin at 486.94% for Q4 2025, down 25494.0% from a year ago — trailing twelve months through Dec 2025 was 417.5% (down 20412.0% YoY), and the annual figure for FY2025 was 417.5%, down 20413.0%.
  • FCF Margin for Q4 2025 was 486.94% at Ocular Therapeutix, down from 359.88% in the prior quarter.
  • Over the last five years, FCF Margin for OCUL hit a ceiling of 52.99% in Q3 2023 and a floor of 486.94% in Q4 2025.
  • Median FCF Margin over the past 5 years was 164.44% (2021), compared with a mean of 209.95%.
  • Biggest five-year swings in FCF Margin: surged 77218bps in 2021 and later crashed -25494bps in 2025.
  • Ocular Therapeutix's FCF Margin stood at 128.24% in 2021, then decreased by -6bps to 135.76% in 2022, then dropped by -14bps to 154.81% in 2023, then crashed by -50bps to 232.0% in 2024, then plummeted by -110bps to 486.94% in 2025.
  • The last three reported values for FCF Margin were 486.94% (Q4 2025), 359.88% (Q3 2025), and 396.97% (Q2 2025) per Business Quant data.